NCT01707316View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Healthy
Interventions
DRUG

Treatment A: Canagliflozin 100 mg

Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.

DRUG

Treatment B: Canagliflozin 300 mg

Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.

OTHER

Treatment C: Placebo

Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.

Trial Locations (1)

Unknown

Beijing

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01707316 - A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter